Nemaura Competitors

Delisted . USA . 
Stock . Nemaura Medical
NMRDDelisted Stock  USD 0.93  0.01  1.06%   
Nemaura Medical competes with Neuropace, CVRx, Orthofix Medical, Artivion, and Bluejay Diagnostics; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Nemaura Medical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Nemaura Medical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Nemaura Medical competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.930.930.93
Details
Intrinsic
Valuation
LowRealHigh
0.740.741.02
Details

Nemaura Medical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Nemaura Medical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Nemaura and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Nemaura Medical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
AORT
+ 0.81
CVRX
OFIX
+ 0.8
CVRX
NVNO
+ 0.79
BJDX
OFIX
+ 0.72
NPCE
AORT
+ 0.64
OFIX
MOVE
+ 0.6
BJDX
  
High negative correlations   
NVNO
- 0.83
HSKA
BJDX
- 0.78
HSKA
MOVE
- 0.75
CVRX
MOVE
- 0.67
OFIX
BJDX
- 0.59
CVRX
MODD
- 0.56
NPCE

Risk-Adjusted Indicators

There is a big difference between Nemaura Pink Sheet performing well and Nemaura Medical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Nemaura Medical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
NPCE  3.45  0.29  0.13  0.24  3.01 
(4.20)
 9.73 
(6.19)
 35.38 
CVRX  4.12  0.98  0.21  1.87  3.55 
(5.18)
 12.31 
(8.22)
 41.08 
OFIX  1.82  0.01  0.02  0.12  2.04 
(1.99)
 3.90 
(3.85)
 12.11 
AORT  1.30 (0.03) 0.00  0.09  1.48 
(1.43)
 2.65 
(2.63)
 9.51 
HSKA  1.18  0.58  0.83  3.62  0.00 
(1.25)
 3.63 
(0.71)
 21.36 
BJDX  6.50 (0.88) 0.00 (1.82) 0.00 
 0.00 
 13.03 
(13.14)
 120.52 
MOVE  3.89 (0.67) 0.00 (0.18) 0.00 
 0.00 
 9.44 
(8.81)
 35.49 
INVO  4.97  0.74  0.05 (0.14) 4.69 
(8.22)
 6.67 
(6.85)
 105.62 
NVNO  2.71 (0.70) 0.00 (1.00) 0.00 
 0.00 
 4.22 
(4.76)
 33.20 
MODD  2.44 (0.03) 0.00  0.18  0.00 
 0.00 
 4.60 
(5.75)
 26.16 
All Fundamental Data

Nemaura Medical Competitive Analysis

The better you understand Nemaura Medical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Nemaura Medical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Nemaura Medical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NMRD NPCE CVRX OFIX AORT HSKA BJDX MOVE INVO NVNO
 1.06 
 0.93 
Nemaura
 9.90 
 10.66 
Neuropace
 4.58 
 15.53 
CVRx
 0.69 
 19.04 
Orthofix
 0.50 
 28.41 
Artivion
 0.00 
 119.99 
Heska
 6.53 
 3.75 
Bluejay
 4.36 
 3.59 
Movano
 3.45 
 0.84 
INVO
 0.29 
 3.40 
EnVVeno
Market Volatility
(90 Days Market Risk)
Very steady
Moderately volatile
Somewhat reliable
Not too volatile
Very steady
Very steady
Dangerous
Very risky
Out of control
Slightly risky
Market Performance
(90 Days Performance)
Very Weak
OK
Good
Modest
Modest
Very Weak
Very Weak
Very Weak
Insignificant
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Quite High
Below Average
Low
Below Average
Dangerous
Very High
Low
Dangerous
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Buy
Strong Buy
Not Available
Not Available
Buy
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Cautious Hold
Cautious Hold
Cautious Hold
Hold
Not Rated
Strong Sell
Cautious Hold
Not Rated
Cautious Hold
Current Ratio
0.99
9.86
16.82
3.15
5.77
6.92
17.41
6.78
1.99
20.79
Net Asset
14.56 M
107.65 M
115.23 M
925.32 M
792.4 M
585.82 M
4.87 M
9.42 M
20.89 M
48.63 M
Profit Margin
N/A
-0.37
-1.24
-0.15
-0.0022
-0.0786
N/A
N/A
-1.23
N/A
EBITDA
(8.17 M)
(22.83 M)
(43.1 M)
(79.45 M)
38.14 M
(20.3 M)
(9.17 M)
(29.12 M)
(6.63 M)
(25.02 M)
Current Valuation
22.58 M
334.85 M
327.09 M
834.78 M
1.5 B
652.94 M
(3.44 M)
11.65 M
15.19 M
12.39 M
Price To Book
122.56
32.39
5.78
1.38
3.91
1.74
0.29
2.23
5.97
1.26
Operating Margin
N/A
-0.2
-0.97
-0.0861
0.0826
-0.094
N/A
-31.99
-1.04
N/A
Retained Earnings
(51.88 M)
(503.81 M)
(477.38 M)
(150.14 M)
(47.91 M)
(168.53 M)
(26.95 M)
(124.38 M)
(57.82 M)
(130.04 M)
Current Asset
9.55 M
N/A
N/A
147.87 M
N/A
41.26 M
N/A
138.64 M
N/A
N/A
Beta
0.046
1.8
1.11
1.05
1.75
1.6
0.73
0.19
1.44
1.22
Number Of Employees
36
184
200
1.63 K
1.5 K
808
10
30
25
31
Shares Outstanding
28.9 M
29.85 M
24.26 M
38.21 M
41.92 M
10.91 M
552.85 K
6.6 M
3.91 M
17.54 M
Cash Flow From Operations
(8.45 M)
(19.7 M)
(39.02 M)
(45.75 M)
18.82 M
(21.81 M)
(8.31 M)
(26.18 M)
(4.76 M)
(18.86 M)
Total Debt
20.03 M
72.39 M
30.61 M
134.2 M
358.34 M
95.6 M
370.11 K
252 K
8.68 M
1.4 M
Return On Equity
-7.24
-2.15
-0.79
-0.21
-0.0029
-0.0473
-1.25
-1.81
-143.59
-0.59
Z Score
-7.48
N/A
N/A
N/A
N/A
8.6
N/A
N/A
N/A
N/A
Return On Asset
-0.49
-0.15
-0.31
-0.0237
0.0229
-0.0251
-0.59
-0.89
-0.27
-0.37
Number Of Shares Shorted
52.57 K
437.93 K
2.52 M
2.51 M
3 M
1.32 M
21.06 K
128.34 K
1.95 K
507.89 K
Book Value Per Share
-0.55
0.33
2.69
13.76
7.27
38.26
18.69
2.54
-1.59
2.7
Current Liabilities
658.01 K
N/A
N/A
52.94 M
N/A
18.8 M
N/A
40.62 M
N/A
N/A
Total Asset
14.56 M
107.65 M
115.23 M
925.32 M
792.4 M
585.82 M
4.87 M
9.42 M
20.89 M
48.63 M
Short Ratio
0.3
6.35
7.07
12.36
16.16
5.41
0.09
3.76
0.04
3.63
Target Price
3.5
14.29
16.5
24.4
33.17
130.0
256.0
30.0
20.0
18.0
Debt To Equity
N/A
1.08
0.003
0.078
1.27
0.26
0.036
0.025
0.6
0.04
Shares Owned By Institutions
7.7
82.89
71.9
92.32
87.09
87.54
0.95
13.84
3.0
29.76
Market Capitalization
2.43 M
318.18 M
376.82 M
727.6 M
1.19 B
1.31 B
2.07 M
27.72 M
3.25 M
59.62 M
Price To Earning
-707.14
N/A
0.19
338.0
N/A
498.39
N/A
39.53
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
0.33
181.5
2.53
N/A
N/A
N/A
N/A
Price To Sales
804.62
4.16
7.97
0.93
3.09
2.6
54.99
27.95
0.56
N/A
Net Income
(14.14 M)
(32.96 M)
(41.2 M)
(151.4 M)
(30.69 M)
(19.89 M)
(9.95 M)
(29.28 M)
(8.03 M)
(23.52 M)
Earnings Per Share
-0.39
-0.98
-2.69
-3.14
-0.03
-1.92
-804.0
-5.8
0.69
-1.29
Shares Owned By Insiders
48.3
4.1
4.39
4.99
5.51
6.45
1.14
17.33
0.6
0.29
Revenue
77.04 K
65.42 M
39.3 M
746.64 M
354 M
257.31 M
N/A
N/A
3.02 M
N/A
Working Capital
(8.73 M)
76.49 M
104.23 M
255.22 M
222.81 M
225.46 M
1.45 M
2.62 M
(6.96 M)
45.55 M
Cash And Equivalents
14.75 M
92.41 M
109.98 M
59.54 M
40.38 M
171.93 M
15.34 M
21.3 M
1.96 M
37.48 M
Cash Per Share
0.61
3.72
5.34
2.98
1.0
15.89
0.76
0.65
0.16
3.96
Gross Profit
(1.48 M)
32.49 M
17.47 M
337.17 M
202.52 M
111.17 M
48.91 K
N/A
535.27 K
N/A
Day Typical Price
0.94
10.28
15.4
19.0
28.53
119.99
3.67
3.51
0.84
3.4
Accumulation Distribution
0.1
0.13
0.0861
0.026
0.0225
N/A
0.12
0.0986
0.0805
0.0233
Market Facilitation Index
0.1
1.37
1.38
0.5
0.65
N/A
0.45
0.36
0.07
0.08
Daily Balance Of Power
(0.10)
0.7007
0.4928
0.26
0.2154
0.0
0.5111
0.4167
(0.43)
(0.12)
Period Momentum Indicator
(0.01)
0.96
0.68
0.13
0.14
N/A
0.23
0.15
(0.03)
(0.01)
Rate Of Daily Change
0.99
1.1
1.05
1.01
1.0
1.0
1.07
1.04
0.97
1.0
Day Median Price
0.95
10.09
15.33
18.98
28.6
119.99
3.63
3.47
0.84
3.4
Price Action Indicator
(0.03)
1.06
0.54
0.12
(0.12)
N/A
0.24
0.19
(0.01)
(0.01)
Coefficient Of Variation
2006.49
915.75
597.77
1363.36
1248.91
452.21
(1,658)
(1,422)
2968.94
(746.41)
Mean Deviation
4.82
3.45
4.12
1.82
1.3
1.18
6.5
3.89
4.97
2.71
Jensen Alpha
0.3478
0.2887
0.9828
0.0062
(0.03)
0.5768
(0.88)
(0.67)
0.7437
(0.70)
Total Risk Alpha
(0.74)
(0.25)
0.0664
(0.20)
(0.14)
0.1707
(2.92)
(1.28)
(1.48)
(1.33)
Sortino Ratio
0.0367
0.1299
0.2143
0.0206
0.0045
0.8262
N/A
N/A
0.0526
N/A
Downside Variance
35.41
12.06
18.86
4.78
2.47
0.3343
N/A
N/A
28.13
N/A
Standard Deviation
6.97
5.31
6.33
2.37
1.69
2.74
13.51
5.61
12.1
4.57
Kurtosis
2.18
10.34
7.29
0.6397
1.16
44.83
28.86
4.45
43.34
19.39
Potential Upside
14.29
9.73
12.31
3.9
2.65
3.63
13.03
9.44
6.67
4.22
Treynor Ratio
(3.78)
0.2405
1.87
0.1233
0.0937
3.62
(1.82)
(0.18)
(0.14)
(1.00)
Maximum Drawdown
35.66
35.38
41.08
12.11
9.51
21.36
120.52
35.49
105.62
33.2
Variance
48.54
28.18
40.11
5.6
2.87
7.52
182.63
31.49
146.3
20.91
Market Risk Adjusted Performance
(3.77)
0.2505
1.88
0.1333
0.1037
3.63
(1.81)
(0.17)
(0.13)
(0.99)
Risk Adjusted Performance
0.047
0.092
0.1366
0.0628
0.0667
0.1762
(0.04)
(0.05)
0.0351
(0.09)
Skewness
1.11
2.41
1.95
0.2943
0.3108
6.25
4.11
(0.86)
6.01
(3.19)
Semi Deviation
5.23
3.01
3.55
2.04
1.48
0.0
N/A
N/A
4.69
N/A
Information Ratio
0.0314
0.085
0.147
0.019
0.0042
0.1742
(0.07)
(0.09)
0.023
(0.16)
Value At Risk
(9.72)
(6.19)
(8.22)
(3.85)
(2.63)
(0.71)
(13.14)
(8.81)
(6.85)
(4.76)
Expected Short fall
(6.03)
(4.20)
(5.18)
(1.99)
(1.43)
(1.25)
N/A
N/A
(8.22)
N/A
Downside Deviation
5.95
3.47
4.34
2.19
1.57
0.5782
N/A
N/A
5.3
N/A
Semi Variance
27.4
9.08
12.63
4.18
2.18
(0.46)
N/A
N/A
21.96
N/A

Nemaura Medical Competition Performance Charts

Five steps to successful analysis of Nemaura Medical Competition

Nemaura Medical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Nemaura Medical in relation to its competition. Nemaura Medical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Nemaura Medical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Nemaura Medical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Nemaura Medical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Nemaura Medical position

In addition to having Nemaura Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Financials ETFs Thematic Idea Now

Financials ETFs
Financials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Financials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Consideration for investing in Nemaura Pink Sheet

If you are still planning to invest in Nemaura Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nemaura Medical's history and understand the potential risks before investing.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY